We measured copeptin , MR-proADM , and MR-proANP concentrations in @,@ patients with NSTE-ACS who were randomized to treatment with ranolazine or placebo in the MERLIN-TIMI @ ( Metabolic Efficiency With Ranolazine for Less Ischemia in Non-ST-Elevation Acute Coronary Syndromes-Thrombolysis In Myocardial Infarction @ ) trial and followed up for @ year .